JenniferJWhelerMD

Oncology • Houston, TX

Physician

Join to view full profile

Are you Dr. Wheler?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 76 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Summary

Dr. Jennifer Wheler, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas and Massachusetts. She is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2002
Weill Cornell MedicineClass of 1999

Certifications & Licensure

MA State Medical License 2016 - 2025
TX State Medical License 2007 - 2015

Clinical Trials

Valproic Acid and Bevacizumab in Patients With Advanced Cancer Start of enrollment: 2007 Jun 01
Completed
Phase 1
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors Start of enrollment: 2007 Nov 01
Suspended
Phase 1
Study of Erlotinib in Combination With Dasatinib Start of enrollment: 2009 Apr 01
Completed
Phase 1
Erlotinib in Combination With Cetuximab Start of enrollment: 2009 Apr 01
Completed
Phase 1
Study of Erlotinib in Combination With Bortezomib Start of enrollment: 2009 Apr 01
Completed
Phase 1
An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status Start of enrollment: 2009 Apr 01
Completed
Phase 1
TTP607 in Refractory Solid Malignancies Start of enrollment: 2010 Mar 01
Withdrawn
Phase 1
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance Start of enrollment: 2010 Sep 07
Completed
Phase 1
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours Start of enrollment: 2011 Jan 01
Completed
Phase 1
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients Start of enrollment: 2011 Oct 07
Completed
Phase 1
Erlotinib in Combination With Pralatrexate in Advanced Malignancies Start of enrollment: 2012 Mar 01
Completed
Phase 1
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Start of enrollment: 2014 Jul 17
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

4 citations
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor−positive Metastatic Breast Cancer or Other Solid Tumors
Alexej Ballhausen, Jennifer J. Wheler, Daniel D. Karp, Sarina Anne Piha-Paul, Siqing Fu, Shubham Pant, Apostolia Maria Tsimberidou, David S. Hong, Vivek Subbiah, Veron...> ;Clinical Cancer Research. 2021 Mar 1
14 citations
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne Velez-Bravo, Tamara G. Barnes, Fredrick B. Ha...> ;Clinical Cancer Research. 2020 Nov 1
33 citations
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
Apostolia Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Anne Piha-Paul, Carrie Cartwright, Russe...> ;Journal of Hematology & Oncology. 2019 Dec 30
11 citations
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
Jeffrey P. Sharman, Jennifer J. Wheler, Lawrence H. Einhorn, Afshin Dowlati, Geoffrey I. Shapiro, John Hilton, John M. Burke, Tanya Siddiqi, Nancy Whiting, Shadia I. J...> ;Investigational New Drugs. 2019 Apr 16
14 citations
Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).
Sneha Berry, Nicolas A. Giraldo, Peter Nguyen, Benjamin Green, Haiying Xu, Aleksandra Ogurtsova, Abha Soni, Farah Succaria, Daphne Wang, Charles Roberts, Julie E. Stei...> ;Journal for Immunotherapy of Cancer. 2019 Feb 13
26 citations
Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study.
Anita Chawla, Filip Janku, Jennifer J. Wheler, Vincent A. Miller, Jason Ryan, Rachel Anhorn, Zhou Zhou, James Signorovitch> ;JCO Precision Oncology. 2017 May 20
15 citations
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
Shumei Kato, Denis Leonardo Fontes Jardim, Faye M. Johnson, Vivek Subbiah, Sarina Anne Piha-Paul, Apostolia Maria Tsimberidou, Gerald S. Falchook, Daniel D. Karp, Ralp...> ;Investigational New Drugs. 2018 Jun 1
30 citations
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients...
Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris, Lillian L. Siu, Lee Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi ...> ;Investigational New Drugs. 2018 Apr 3
21 citations
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.
Divya Sakamuri, Isabella C. Glitza, Sonia L. Betancourt Cuellar, Vivek Subbiah, Siqing Fu, Apostolia Maria Tsimberidou, Jennifer J. Wheler, David S. Hong, Aung Naing, ...> ;Molecular Cancer Therapeutics. 2017 Jan 1
19 citations
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Vikas Dembla, Roman Groisberg, KR Hess, Siqing Fu, Jennifer J. Wheler, David S. Hong, Filip Janku, Ralph Zinner, Sarina Anne Piha-Paul, Vinod Ravi, Robert S. Benjamin,...> ;Scientific Reports. 2017 Nov 21
109 citations
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study
Apostolia-Maria Tsimberidou, David S. Hong, Yang Ye, Carrie Cartwright, Jennifer J. Wheler, Gerald S. Falchook, Aung Naing, Siqing Fu, Sarina Anne Piha-Paul, Filip Jan...> ;JCO Precision Oncology. 2017 Sep 8
25 citations
A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
Ignace Vergote, David Smith, Raanan Berger, Razelle Kurzrock, Nicholas J. Vogelzang, Avishay Sella, Jennifer J. Wheler, Yihua Lee, Paul Foster, Ron Weitzman, Ronald J....> ;European Journal of Cancer. 2017 Sep 1
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.
Jennifer Brooke Goldstein, Chad Tang, Kenneth R. Hess, David S. Hong, Vivek Subbiah, Filip Janku, Siqing Fu, Daniel D. Karp, Aung Naing, Apostolia Maria Tsimberidou, J...> ;Oncotarget. 2017 Aug 3
529 citations
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung-Ju Ahn, Jeeyun Lee, Todd M. Bauer, Anna F. Farago, Jennifer J. Wheler, Stephen V. Liu, Rob...> ;Cancer Discovery. 2017 Feb 9
19 citations
Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
Jennifer J. Wheler, David G. Mutch, Joanne Lager, Christelle Castell, Li Liu, Jason Jiang, Anne M. Traynor> ;The Oncologist. 2017 Apr 1
8 citations
Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
Ishwaria Mohan Subbiah, Jennifer J. Wheler, Kenneth R. Hess, David S. Hong, Aung Naing, Siqing Fu, Razelle Kurzrock, Apostolia Maria Tsimberidou> ;International Journal of Cancer. 2017 Jan 1
33 citations
Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
Filip Janku, Haojie Huang, Takeo Fujii, Dawne N. Shelton, Kiran Madwani, Siquing Fu, Apostolia-Maria Tsimberidou, Sarina Anne Piha-Paul, Jennifer J. Wheler, Ralph Zinn...> ;Annals of Oncology. 2017 Mar 1
34 citations
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park, Ignacio Garrido-Laguna, Aung Naing, Siqing Fu, Gerald S. Falchook, Sarina Anne Piha-Paul, Jennifer J. Wheler, David S. Hong, Apostolia Maria Tsimberidou...> ;Oncotarget. 2016 Aug 31
34 citations
Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.
Jennifer J. Wheler, Johnique T. Atkins, Filip Janku, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda M...> ;Oncoscience. 2016 Jun 30
168 citations
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Jennifer J. Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald Steven Falchook, Apostolia Maria T...> ;Cancer Research. 2016 Jul 1
12 citations
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
Mehmet Asim Bilen, Amy Patel, Kenneth R. Hess, Javier Munoz, Naifa L. Busaidy, Jennifer J. Wheler, Filip Janku, Gerald S. Falchook, David S. Hong, Funda Meric-Bernstam...> ;Cancer Chemotherapy and Pharmacology. 2016 Jun 10
65 citations
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
Filip Janku, Helen J. Huang, Bart Claes, Gerald S. Falchook, Siqing Fu, David S. Hong, Nishma M. Ramzanali, Giovanni Nitti, Goran Cabrilo, Apostolia Maria Tsimberidou,...> ;Molecular Cancer Therapeutics. 2016 Jun 1
9 citations
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
Ming Mo Hou, Zhijie Wang, Filip Janku, Sarina Anne Piha-Paul, Aung Naing, David S. Hong, Shannon N. Westin, Robert L. Coleman, Anil K. Sood, Apostolia Maria Tsimberido...> ;Oncotarget. 2016 Apr 27
5 citations
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Rabih Said, Sarina Anne Piha-Paul, Siqing Fu, Gerald S. Falchook, Filip Janku, Jennifer J. Wheler, Ralph Zinner, David S. Hong, Razelle Kurzrock, Apostolia Maria Tsimb...> ;Cancer Chemotherapy and Pharmacology. 2016 Apr 16
18 citations
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
Xiaochun Liu, Susan Kambrick, Siqing Fu, Aung Naing, Vivek Subbiah, George R. Blumenschein, Bonnie S. Glisson, Merrill S. Kies, Apostolia Maria Tsimberidou, Jennifer J...> ;Oncotarget. 2016 Feb 22
Join now to see all

Press Mentions

Great Danes: Two Nordic Biotechs Name Their Chief Executives; Axel Hoos Bids Adieu to GlaxoSmithKline, Becomes CEO of Small Oncology PlayerJuly 9th, 2021
Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. To Scientific Advisory Board Member and Clinical Consultant RolesJuly 6th, 2021
Moderna Dips into J&J's Talent Pool for Tal Zaks' Replacement; Jim Mullen Chooses Next Chief Scientist at Editas MedicineJune 18th, 2021
Join now to see all

Hospital Affiliations

University of Texas M.D. Anderson Cancer CenterHouston, Texas